Suramin — CAS 145-63-1

Suramin is a polysulfonated naphthylurea compound with antiparasitic and antineoplastic properties. Originally developed for African sleeping sickness (Human African Trypanosomiasis), Suramin has gained renewed research interest as an ectoenzyme inhibitor, anti-cancer agent, and has been investigated for autism spectrum disorder and COVID-19. Mediocon Inc supplies high-purity Suramin API from its GMP-certified manufacturing facility in Maharashtra, India.

• African sleeping sickness (HAT)
• Onchocerciasis (River Blindness)
• Investigational antineoplastic
• Research applications

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support